Close Menu


The panel is designed to simultaneously detect 21 respiratory pathogens including several atypical bacteria in a single closed-tube system.

As part of the deal, Affymetrix will sell Luminex's Magpix, Luminex 200, and Flexmap 3D multiplexed assay platforms in specified geographies.

The firm plans to officially launch and introduce the PCR-based platform and herpes assay over the next several weeks.

Previously for research use only, the Respiratory Pathogen Test for the Verigene System is Nanosphere's fifth infectious disease test to receive FDA clearance.

The Northbrook, Illinois-based molecular diagnostics firm said that sales for its blood culture tests in the quarter increased 87 percent year over year.

The firm saw a profitable quarter driven by increases in assay sales and royalty revenues, despite a $7.1 million legal settlement with Enzo Life Sciences.

The firm raised $8 million since May and is no longer obligated to raise an additional $2 million by January 2016, per the original terms of the loan facility.

The firm expects to receive both FDA clearance and CE-IVD marking for the system and assay by the end of 2015 and has more assays in development.

Luminex will pay Enzo Biochem $7.1 million to settle a lawsuit alleging infringement of patents for oligonucleotides and solid supports for fixed nucleic acids.

The firm sold shares of preferred stock and warrants to purchase common stock. It expects net proceeds of approximately $4.0 million.


Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.